So far Trelegy has been launched in 30 countries and continues to roll out, with recent approvals in Japan and China setting up launches in those big markets later this year.

Fluticasone furoate, umeclidinium, vilanterol 100/62.5/25mcg, 200/62.5/25mcg; per inh; dry pwd for oral inhalation. Trelegy Ellipta is supplied as a disposable light grey and beige plastic inhaler ...

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a prescription drug used to treat COPD. With COPD, you have lung damage that worsens over time ...

The FDA has approved GlaxoSmithKline’s Trelegy Ellipta inhaler for asthma in adults, adding to its existing use in chronic obstructive pulmonary disease (COPD), stealing a march on rivals ...

Downgrading GoodRx to a sell rating on recent decline fundamentals. GoodRx's revenue growth is decelerating, with significant reliance on retail partnerships and cyclical transactional revenue ...

GoodRx has officially entered the weight loss drug market by offering an exclusive discount on the once-daily oral medication Qsymia. Through GoodRx, patients with a valid prescription can ...

Shayna Chamberlin's monthly prescription went from $210 to $37. She credits GoodRx. "It saved me $300 this year alone," Chamberlin said. "I know how insane health care prices are as someone who ...

If you're one of the many Americans struggling to afford prescription medication, GoodRx's deal with Walgreens could help you save the next time you're at the pharmacy. Prices on nearly 200 ...

To find out whether they really work, we tried four of them—GoodRx, LowestMed, Mobile Rx Card, and WeRx—to price a month's supply of the cholesterol-lowering drug Lipitor (40 milligrams ...

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic ...

Full Year 2024 Adjusted EBITDA: Expected over $255 million, up about 18% from 2023. GoodRx Holdings Inc (NASDAQ:GDRX) reported a 6% year-over-year increase in total revenue for the second quarter ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...